AllianceBernstein
DSGN icon

AllianceBernstein’s Design Therapeutics DSGN Stock Holding History

AllianceBernstein’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$460K Sell
43,230
-2,890
-6% -$36K ﹤0.01% 2771
2026
Q1 		$433K Hold
46,120
– – ﹤0.01% 2709
2025
Q4 		$433K Hold
46,120
– – ﹤0.01% 2728
2025
Q3 		$347K Buy
46,120
+1,090
+2% +$5.46K ﹤0.01% 2871
2025
Q2 		$152K Buy
45,030
+2,940
+7% +$11K ﹤0.01% 3112
2025
Q1 		$162K Hold
42,090
– – ﹤0.01% 2975
2024
Q4 		$260K Hold
42,090
– – ﹤0.01% 2946
2024
Q3 		$226K Hold
42,090
– – ﹤0.01% 3004
2024
Q2 		$141K Buy
42,090
+4,590
+12% +$17.9K ﹤0.01% 3080
2024
Q1 		$151K Hold
37,500
– – ﹤0.01% 2973
2023
Q4 		$99.4K Sell
37,500
-3,900
-9% -$8.93K ﹤0.01% 3068
2023
Q3 		$97.7K Hold
41,400
– – ﹤0.01% 3073
2023
Q2 		$261K Buy
41,400
+10,200
+33% +$62.4K ﹤0.01% 2915
2023
Q1 		$180K Buy
31,200
+3,600
+13% +$26.9K ﹤0.01% 2934
2022
Q4 		$283K Buy
27,600
+6,400
+30% +$86.7K ﹤0.01% 2895
2022
Q3 		$354K Buy
21,200
+7,200
+51% +$143K ﹤0.01% 2794
2022
Q2 		$196K Buy
+14,000
New +$189K ﹤0.01% 3032

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein's DSGN Position: Q2 2026 in Review

AllianceBernstein reduced its Design Therapeutics (DSGN) stake by 6.3% in Q2 2026, selling an estimated $36K and leaving 43,230 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #2771.

AllianceBernstein first reported a position in DSGN in Q2 2022 and has held it in 17 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • AllianceBernstein held 43,230 shares of Design Therapeutics worth $460K as of Q2 2026.
  • AllianceBernstein sold 2,890 Design Therapeutics shares in Q2 2026, an estimated $36K.
  • Design Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2771 holding.
  • AllianceBernstein first reported a position in Design Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.